Free Trial
NASDAQ:ETON

Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

Eton Pharmaceuticals logo
$17.14 +1.88 (+12.32%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$17.16 +0.02 (+0.12%)
As of 08/8/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eton Pharmaceuticals Stock (NASDAQ:ETON)

Key Stats

Today's Range
$14.73
$17.20
50-Day Range
$13.50
$18.84
52-Week Range
$3.52
$21.48
Volume
804,028 shs
Average Volume
414,883 shs
Market Capitalization
$459.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.67
Consensus Rating
Buy

Company Overview

Eton Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

ETON MarketRank™: 

Eton Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 670th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eton Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Eton Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eton Pharmaceuticals is -107.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eton Pharmaceuticals is -107.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eton Pharmaceuticals has a P/B Ratio of 18.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.30% of the float of Eton Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eton Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Eton Pharmaceuticals has recently increased by 29.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eton Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eton Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.30% of the float of Eton Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eton Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Eton Pharmaceuticals has recently increased by 29.24%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eton Pharmaceuticals has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Eton Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    11 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $504,318.00 in company stock.

  • Percentage Held by Insiders

    16.03% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 27.86% of the stock of Eton Pharmaceuticals is held by institutions.

  • Read more about Eton Pharmaceuticals' insider trading history.
Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ETON Stock News Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
See More Headlines

ETON Stock Analysis - Frequently Asked Questions

Eton Pharmaceuticals' stock was trading at $13.32 at the beginning of 2025. Since then, ETON stock has increased by 28.7% and is now trading at $17.14.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) issued its earnings results on Thursday, August, 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.09. The company earned $18.93 million during the quarter, compared to analysts' expectations of $16.71 million. Eton Pharmaceuticals had a negative net margin of 7.10% and a negative trailing twelve-month return on equity of 0.74%.
Read the conference call transcript
.

Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

Top institutional shareholders of Eton Pharmaceuticals include Geode Capital Management LLC (2.21%), Westside Investment Management Inc. (1.76%), Acadian Asset Management LLC (1.46%) and Connor Clark & Lunn Investment Management Ltd. (0.83%). Insiders that own company stock include Opaleye Management Inc, Sean Brynjelsen and David Krempa.
View institutional ownership trends
.

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/07/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ETON
CIK
1710340
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$35.00
Low Price Target
$26.00
Potential Upside/Downside
+73.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.82 million
Net Margins
-7.10%
Pretax Margin
-9.30%
Return on Equity
-0.74%
Return on Assets
-0.25%

Debt

Debt-to-Equity Ratio
1.23
Current Ratio
1.97
Quick Ratio
1.43

Sales & Book Value

Annual Sales
$39.01 million
Price / Sales
11.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
18.23

Miscellaneous

Outstanding Shares
26,820,000
Free Float
22,519,000
Market Cap
$459.69 million
Optionable
Optionable
Beta
1.13

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ETON) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners